Taysha Gene Therapies, Inc. Common Stock
Here’s whether Taysha Gene Therapies, Inc. Common Stock (TSHA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.94% over 10 days); RSI 55 — healthy momentum range; strong 1-year return of +112.2%; 3-month momentum positive (+10.9%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 16.6% off its 52-week high. Score: +5/7.
TSHA is holding above its long-term 200-day MA ($5.35) but has slipped below the 50-day MA ($6.14), pointing to short-term weakness in an otherwise intact trend. An RSI of 55.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +112.2% compares to +20.5% for SPY (beat the market by 91.7%).